Jay Venkatesan, CEO, Angion Biomedica (ANGN)
Jay Venkatesan, M.D., is the President, Chief Executive Officer, and Chairman of Angion Biomedica Corp.
Prior to Angion, Dr. Venkatesan served as President and Director of Alpine Immune Sciences (ALPN), which he co-founded as a Managing Partner of Alpine BioVentures.
Previously, Dr. Venkatesan was the founder and portfolio manager of Ayer Capital, a global health care fund.
Prior to that, he served as a director at Brookside Capital, part of Bain Capital, where he co-managed health care investments.
He was also a consultant at McKinsey & Co. and a venture investor with Patricof & Co. Ventures (now Apax Partners).
He received his M.D. from the University of Pennsylvania School of Medicine, his MBA from the Wharton School of the University of Pennsylvania, and his B.A. from Williams College.
In this 3,772 word interview, exclusively in the Wall Street Transcript, Dr. Venkatesan details his company’s recovery from disappointing Phase II results towards a more promising drug in development.
“It is really hard to predict how investors are going to look at the overall biotech space, but my take is probably beginning in the third quarter things may start to look better for the sector.
For Angion specifically, we will be in a position to share more ANG-3070 efficacy data from animal models in pulmonary fibrosis in the middle of the year. We will also be closer to filing an IND in idiopathic pulmonary fibrosis — IPF — and starting our clinical work in IPF.
The reason I’m focusing on the IPF opportunity is that our kidney study is already ongoing.
We have said we expect to finish enrolling JUNIPER, our Phase II trial in FSGS and IgAN patients, by the end of this year and should have data in the first half of next year.
When we talk to investors, they do understand how successful nintedanib has been for Boehringer Ingelheim, how significant the market opportunity is, how meaningful the unmet medical need is in IPF.
But it’s a little bit of a disconnect for some investors when we talk about our program. We have overlapping targets with OFEV, and we have what looks like, in our healthy volunteers study anyway, safety and tolerability that looks outstanding.
But then we say we’re initially studying ANG-3070 in kidney fibrosis, a condition where OFEV isn’t used and was not extensively studied. That creates a little bit of a question from investors of, “Well, if this looks a lot like it could be an improved OFEV, why are you targeting kidney fibrosis and not lung fibrosis?”
How we started down the kidney path ahead of the lung path is complicated, but we’re committed to doing both.”
Get more details from Dr. Venkatesan, CEO of Angion Biomedica (NASD: ANGN) by reading the entire 3,772 word interview, exclusively in the Wall Street Transcript.
70 Pounds of Lithium in Each Tesla (NASD: TSLA) Fuels Christopher Jones' Westwater Resources (NASD: WWR)
December 11, 2017
Lisa Conte, Jaguar Health (NASD: JAGX) CEO, Details Veterinary and Human Potential for Her New Drug Discovery
March 23, 2022
Novartis (NYSE:NVS) and Genentech (VTX:ROG) Veterans Peter Maag and Sasha King Team Up at Diagnostic Testing Company CareDx, Inc. (NASD:CDNA)
October 06, 2017
Mohan Naidu of Oppenheimer & Company Bangs the Table for Healthequity (NASD:HQY)
October 06, 2017
Mason King of Luther King Capital Makes Banc of California (NASD:BANC) a Top Pick
October 31, 2017
